Ibio, Inc. products

Pipeline- Therapeutics

IBIO - Immuno Oncology Therapeutics

Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the immune responses to tumor cells. The Treg is a type of T cell that is important in preventing autoimmunity by keeping effector T cells [Teffs] “in-check” to prevent destruction of healthy tissues. However, around tumors, Tregs create an immunosuppressive environment and block the work of Teffs to do what they do well – kill cancer cells. So, targeting depletion of Tregs to control tumors has emerged as an area of interest in oncology over the past several years.

Ibio - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics

Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, irreversible loss of lung function. The average life expectancy after an IPF diagnosis is 3-5 years.¹ Because there is no cure and no therapy has been shown to halt or reverse the progressive deterioration of lung function, the primary goal of IPF treatment is to slow disease progression, maintain or improve quality of life, and prolong survival. Systemic sclerosis is a rare chronic disease of uncertain etiology characterized by diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs. A number of medications can slow the progression of specific existing symptoms or temporarily reduce the development of new symptoms, but there remains an unmet need for more effective treatment.

Platform

Ibio - Discovery Engine Platform Technology

Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.¹ Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both potentially due to binding the wrong epitope.